Washington · 2025–26 Regular Sessions · Bill
HB 1725: Biosimilar medicines
In committee Official data
- Introduced
- In committee
- Passed one chamber
- Passed both chambers
- Enacted
Last official action: ·Record last updated:
Plain-language summary
HB 1725 is a bill introduced in the Washington House on January 30, 2025. According to its official title, it concerns: Increasing access to biosimilar medicines. Primary sponsor: My-Linh Thai (D). It lists 4 additional sponsors. Most recent recorded action (January 12, 2026): By resolution, reintroduced and retained in present status.
Generated automatically from the official title, sponsor list, and status record only. It does not characterize the bill’s purpose or effects. How summaries are written
Official title
AN ACT Relating to reducing prescription drug costs by eliminating barriers impeding access to biosimilar medicines;
Nonpartisan staff bill reports (analyses) are available on the official bill page.
Sponsors
Sponsors by party (alphabetical): Democratic 5
| Name | Role | Party | Chamber | District |
|---|---|---|---|---|
| My-Linh Thai | Primary sponsor | Democratic | House | 41 |
| Davina Duerr | Co-sponsor | Democratic | House | 1 |
| Nicole Macri | Co-sponsor | Democratic | House | 43 |
| Lisa Parshley | Co-sponsor | Democratic | House | 22 |
| Clyde Shavers | Co-sponsor | Democratic | House | 10 |
“Support” is shown only as formal sponsorship recorded by the legislature. Roll-call votes are available on the official bill page.
Recent official actions
- By resolution, reintroduced and retained in present status.
- First reading, referred to Health Care & Wellness.